Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET

The positron emission tomography (PET) radiotracer [18F]MK‐6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity to medial temporal and neocortical NFTs, and low within‐brain background. Objectives were to develop and validate a reproducible, clinically relevant visual read method supporting [18F]MK‐6240 use to identify and stage AD subjects versus non‐AD and controls.

• Publication year

  2023

• Venue

  Alzheimer's & Dementia

• Publication date

  2023-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/trc2.12372PMID 36873926PMCID 9983143
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET

  2023cited by this paper
• Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease

  2022cited by this paper
• A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18F-MK-6240 PET

  2022cited by this paper
• Optimizing quantification of MK6240 tau PET in unimpaired older adults

  2022cited by this paper
• Kinetic evaluation and assessment of longitudinal changes in reference region and extracerebral [18F]MK-6240 PET uptake

  2022cited by this paper
• A Visual Interpretation Algorithm for Assessing Brain Tauopathy with [18F]MK6240 Positron Emission Tomography

  2022cited by this paper
• Donanemab in Early Alzheimer's Disease.

  2021cited by this paper
• Patterns of tau pathology identified with 18F‐MK‐6240 PET imaging

  2021cited by this paper
• Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects

  2021cited by this paper
• Early stages of tau pathology and its associations with functional connectivity, atrophy and memory

  2021cited by this paper
• The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography

  2021cited by this paper
• Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET

  2020cited by this paper
• Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment

  2020cited by this paper
• 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.

  2020cited by this paper
• IC‐P‐169: PATTERNS OF TAU PATHOLOGY IDENTIFIED WITH 18F‐MK‐6240 PET IMAGING

  2019cited by this paper
• Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue

  2019cited by this paper
• Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease

  2019cited by this paper
• Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

  2019cited by this paper
• The neuropathological diagnosis of Alzheimer’s disease

  2019cited by this paper
• The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

  2019cited by this paper
• Test–retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer’s disease

  2019cited by this paper
• Tau‐positron emission tomography correlates with neuropathology findings

  2019cited by this paper
• Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.

  2018cited by this paper
• In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls

  2018cited by this paper
• Enhanced Tau Aggregation in the Presence of Amyloid β.

  2017cited by this paper
• The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain

  2017cited by this paper
• Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging

  2017cited by this paper
• Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).

  2016cited by this paper
• Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol β-amyloid PET brain images

  2016cited by this paper
• Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

  2016cited by this paper
• A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

  2016cited by this paper
• Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles

  2016cited by this paper
• Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging

  2016cited by this paper
• PET Imaging of Tau Deposition in the Aging Human Brain.

  2016cited by this paper
• Primary age-related tauopathy (PART): a common pathology associated with human aging

  2014cited by this paper
• Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data

  2014cited by this paper
• National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

  2012cited by this paper
• Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

  2012cited by this paper
• Reducing between scanner differences in multi-center PET studies

  2009cited by this paper
• Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

  2006cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

  1992cited by this paper
• Measuring nominal scale agreement among many raters.

  1971cited by this paper
• Journal of Cerebral Blood Flow and Metabolism Measurement of Radiotracer Concentration in Brain Gray Matter Using Positron Emission Tomography: Mri-based Correction for Partial Volume Effects

  year unknowncited by this paper

• Synthesis and Evaluation of Radioiodinated [125I]7‐Iodo‐5H‐Pyrido[4,3‐B]Indole ([125I]CTAU) in Postmortem Human Alzheimer's Disease Brain

  2026cites this paper
• Off-target binding of 18F-MK-6240 tau PET imaging demonstrated by high spatial resolution dedicated brain PET scanner.

  2026cites this paper
• The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies

  2025cites this paper
• Cognitive reserve predicts baseline tau burden in the U.S. POINTER trial imaging cohort

  2025cites this paper
• Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

  2025cites this paper
• Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

  2025cites this paper
• Tau pathology is associated with postsynaptic metabotropic glutamate receptor 5 (mGluR5) in early Alzheimer's disease in a sex‐specific manner

  2025cites this paper
• Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers

  2025cites this paper
• The Current Role of Tau PET Imaging in Neurodegeneration.

  2025cites this paper
• Evaluation of a Sensitive Visual Read Algorithm for Assessing 3R/4R Tau PET Images

  2025cites this paper
• Recent advances in neuroimaging of Alzheimer's disease and related dementias

  2025cites this paper
• Synaptic loss pattern is constrained by brain connectome and modulated by phosphorylated tau in Alzheimer’s disease

  2025cites this paper
• Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models

  2024cites this paper
• The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease

  2024cites this paper
• Tau pathology is associated with synaptic density and longitudinal synaptic loss in Alzheimer’s disease

  2024cites this paper
• Development of a novel phantom for tau PET imaging.

  2024cites this paper
• Head‐to‐Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study

  2024cites this paper
• Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model

  2024cites this paper
• Reproducibility of [18F]MK-6240 kinetics in brain studies with shortened dynamic PET protocol in healthy/cognitively normal subjects

  2024cites this paper
• Visual reading for [18F]Florzolotau Tau PET scans in progressive supranuclear palsy

  2024cites this paper
• Regional differences in glucose metabolic decline and tau deposition in the Alzheimer's continuum brain

  2024cites this paper
• Visual read of [F‐18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer's disease

  2024cites this paper
• Test–retest performance of [ 18 F]MK-6240 tau burden and relative delivery indices in cognitively normal older subjects using PET/MRI

  2024cites this paper
• Development, initial validation, and application of a visual read method for [18F]MK‐6240 tau PET

  2023cites this paper
• Performance of a [18F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies

  2023cites this paper
• Advanced brain imaging for the diagnosis of Alzheimer disease

  2023cites this paper
• Towards in vivo PET imaging of primary age-related tauopathy.

  2023cites this paper
• Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer’s disease

  2023cites this paper
• Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo

  2023cites this paper
• Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment

  2023cites this paper